Cardiac and respiratory dysfunction in duchenne muscular dystrophy and the role of second messengers

Medicinal Research Reviews

Volumn 33, Issue 5, 2013, Pages 1174-1213

  Mosqueira, Matias ^a   Zeiger, Ulrike ^b   Förderer, Moritz ^a   Brinkmeier, Heinrich ^b   Fink, Rainer Ha ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Ca2+ NO signaling; Cardiomyopathy; Dystrophin; Skeletal muscle; Ventilation

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ATALUREN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUPIVACAINE; CALCIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DYSTROPHIN; INDUCIBLE NITRIC OXIDE SYNTHASE; ISOSORBIDE DINITRATE; LOSARTAN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; P 188; PIRFENIDONE; PREDNISONE; RYANODINE RECEPTOR; SILDENAFIL; UNCLASSIFIED DRUG; UTROPHIN;

ARTICLE; BLOOD FLOW; BREATHING MUSCLE; CALCIUM CELL LEVEL; CARDIOPULMONARY INSUFFICIENCY; CAUSE OF DEATH; CELL DEATH; COSTAMERE; CYTOPLASM; CYTOSOL; DUCHENNE MUSCULAR DYSTROPHY; FORCED VITAL CAPACITY; GENE THERAPY; HEART FAILURE; HEART MUSCLE; HEART MUSCLE FIBROSIS; HUMAN; HYPERCAPNIA; HYPOVENTILATION; HYPOXEMIA; LEG MUSCLE; MACROPHAGE ACTIVATION; MUSCLE ATROPHY; MUSCLE BIOPSY; MUSCLE TISSUE; MUSCULAR DYSTROPHY; MYOFIBROSIS; NITROSYLATION; NONHUMAN; POSITIVE FEEDBACK; PROTEIN DEGRADATION; QUALITY OF LIFE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESPIRATORY CARE; SARCOLEMMA; SECOND MESSENGER; SKELETAL MUSCLE; TIDAL VOLUME; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

CA2+-NO SIGNALING; CARDIOMYOPATHY; DYSTROPHIN; SKELETAL MUSCLE; VENTILATION;

ANIMALS; DISEASE MODELS, ANIMAL; GLYCOPROTEINS; HEART; HUMANS; LUNG; MUSCULAR DYSTROPHY, DUCHENNE; SECOND MESSENGER SYSTEMS;

EID: 84881218944     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.21279     Document Type: Article

References (346)

1. Engel AG, Franzini-Armstrong C. Myology. New York: McGraw-Hill; 1994.
2. Hoffman EP, Brown RH, Kunkel LM. Dystrophin: The protein product of the Duchenne muscular dystrophy locus. Cell 1987;51:919-928.
3. Hoffman EP, Monaco AP, Feener CC, Kunkel LM. Conservation of the Duchenne muscular dystrophy gene in mice and humans. Science 1987;238(4825):347-350.
4. Koenig M, Monaco AP, Kunkel LM. The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. Cell 1988;53(2):219-226.
5. Kaspar RW, Allen HD, Montanaro F. Current understanding and management of dilated cardiomyopathy in Duchenne and Becker muscular dystrophy. J Am Acad Nurse Pract 2009;21(5):241-249.
6. Chakkalakal JV, Thompson J, Parks RJ, Jasmin BJ. Molecular, cellular, and pharmacological therapies for Duchenne/Becker muscular dystrophies. FASEB J 2005;19(8):880-891.
7. Khurana TS, Davies KE. Pharmacological strategies for muscular dystrophy. Nat Rev Drug Discov 2003;2(5):379-390.
8. Bogdanovich S, Perkins KJ, Krag TO, Khurana TS. Therapeutics for Duchenne muscular dystrophy: Current approaches and future directions. J Mol Med 2004;82(2):102-115.
9. Wallace GQ, McNally EM. Mechanisms of muscle degeneration, regeneration, and repair in the muscular dystrophies. Annu Rev Physiol 2009;71:37-57.
10. Brenman JE, Chao DS, Gee SH, McGee AW, Craven SE, Santillano DR, Wu Z, Huang F, Xia H, Peters MF, Froehner SC, Bredt DS. Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and α1-syntrophin mediated by PDZ domains. Cell 1996;84(5):757-767.
11. Ibraghimov-Beskrovnaya O, Ervasti JM, Leveille CJ, Slaughter CA, Sernett SW, Campbell KP. Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix. Nature 1992;355(6362):696-702.
12. Rybakova IN, Patel JR, Ervasti JM. The dystrophin complex forms a mechanically strong link between the sarcolemma and costameric actin. J Cell Biol 2000;150(5):1209-1214.
13. Yoshida M, Ozawa E. Glycoprotein complex anchoring dystrophin to sarcolemma. J Biochem 1990;108(5):748-752.
14. Ervasti JM, Ohlendieck K, Kahl SD, Gaver MG, Campbell KP. Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature 1990;345(6273):315-319.
15. Mitsui T, Kawai H, Kawajiri M, Kunishige M, Aki K, Saito S. Induction of dystrophin-associated proteins together with nicotinic acetylcholine receptors by denervation in the absence of dystrophin in skeletal muscles of mdx mice. Biochem Biophys Res Commun 1996;224(3):802-807.
16. Mitsui T, Kawajiri M, Kunishige M, Endo T, Akaike M, Aki K, Matsumoto T. Functional association between nicotinic acetylcholine receptor and sarcomeric proteins via actin and desmin filaments. J Cell Biochem 2000;77(4):584-595.
17. v1.5 is regulated by a multiprotein complex composed of syntrophins and dystrophin. Circ Res 2006;99(4):407-414.
18. + overload and enhanced cell death. J Gen Physiol 2008;132(2):199-208.
19. Woolf PJ, Lu S, Cornford-Nairn R, Watson M, Xiao XH, Holroyd SM, Brown L, Hoey AJ. Alterations in dihydropyridine receptors in dystrophin-deficient cardiac muscle. Am J Physiol Heart Circ Physiol 2006;290(6):H2439-H2445.
20. Frigeri A, Nicchia GP, Nico B, Quondamatteo F, Herken R, Roncali L, Svelto M. Aquaporin-4 deficiency in skeletal muscle and brain of dystrophic mdx mice. FASEB J 2001;15(1):90-98.
21. Frigeri A, Nicchia GP, Verbavatz JM, Valenti G, Svelto M. Expression of aquaporin-4 in fast-twitch fibers of mammalian skeletal muscle. J Clin Invest 1998;102(4):695-703.
22. Sabourin J, Lamiche C, Vandebrouck A, Magaud C, Rivet J, Cognard C, Bourmeyster N, Constantin B. Regulation of TRPC1 and TRPC4 cation channels requires an α1-syntrophin-dependent complex in skeletal mouse myotubes. J Biol Chem 2009;284(52):36248-36261.
23. Vandebrouck A, Sabourin J, Rivet J, Balghi H, Sebille S, Kitzis A, Raymond G, Cognard C, Bourmeyster N, Constantin B. Regulation of capacitative calcium entries by α1-syntrophin: association of TRPC1 with dystrophin complex and the PDZ domain of α1-syntrophin. FASEB J 2007;21(2):608-617.
24. Johnson EK, Zhang L, Adams ME, Phillips A, Freitas MA, Froehner SC, Green-Church KB, Montanaro F. Proteomic analysis reveals new cardiac-specific dystrophin-associated proteins. PLoS One 2012;7(8):e43515.
25. Hansen CG, Nichols BJ. Exploring the caves: Cavins, caveolins and caveolae. Trends Cell Biol 2010;20(4):177-186.
26. 2+ channel inactivation of rodent cardiomyocytes. Pflugers Arch 2010;460(4):719-730.
27. Pankonien I, Alvarez JL, Doller A, Kohncke C, Rotte D, Regitz-Zagrosek V, Morano I, Haase H. Ahnak1 is a tuneable modulator of cardiac Ca(v)1.2 calcium channel activity. J Muscle Res Cell Motil 2011;32(4-5):281-290.
28. Kumarapeli AR, Wang X. Genetic modification of the heart: chaperones and the cytoskeleton. J Mol Cell Cardiol 2004;37(6):1097-1109.
29. Cheng H, Zheng M, Peter AK, Kimura K, Li X, Ouyang K, Shen T, Cui L, Frank D, Dalton ND, Gu Y, Frey N, Peterson KL, Evans SM, Knowlton KU, Sheikh F, Chen J. Selective deletion of long but not short Cypher isoforms leads to late-onset dilated cardiomyopathy. Hum Mol Genet 2011;20(9):1751-1762.
30. Zheng M, Cheng H, Li X, Zhang J, Cui L, Ouyang K, Han L, Zhao T, Gu Y, Dalton ND, Bang ML, Peterson KL, Chen J. Cardiac-specific ablation of Cypher leads to a severe form of dilated cardiomyopathy with premature death. Hum Mol Genet 2009;18(4):701-713.
31. Zhou Q, Chu PH, Huang C, Cheng CF, Martone ME, Knoll G, Shelton GD, Evans S, Chen J. Ablation of Cypher, a PDZ-LIM domain Z-line protein, causes a severe form of congenital myopathy. J Cell Biol 2001;155(4):605-612.
32. Ervasti JM, Campbell KP. A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin. J Cell Biol 1993;122(4):809-823.
33. Petrof BJ, Shrager JB, Stedman HH, Kelly AM, Sweeney HL. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci USA 1993;90:3710-3714.
34. Coirault C, Lambert F, Pourny J-C, Lecarpentier Y. Velocity of actomyosin sliding in vitro is reduced in dystrophic mouse diaphragm. Am J Respir Crit Care Med 2002;165(2):250-253.
35. Divet A, Lompré AM, Huchet-Cadiou C. Effect of cyclopiazonic acid, an inhibitor of the sarcoplasmic reticulum Ca-ATPase, on skeletal muscles from normal and mdx mice. Acta Physiol Scand 2005;184(3):173-186.
36. 2+. J Physiol 1990;420(1):337-353.
37. Tutdibi O, Brinkmeier H, Rüdel R, Föhr KJ. Increased calcium entry into dystrophin-deficient muscle fibres of MDX and ADR-MDX mice is reduced by ion channel blockers. J Physiol 1999;515(3):859-868.
38. Vandebrouck A, Ducret T, Basset O, Sebille S, Raymond G, Ruegg U, Gailly P, Cognard C, Constantin B. Regulation of store-operated calcium entries and mitochondrial uptake by minidystrophin expression in cultured myotubes. FASEB J 2006;20(1):136-138.
39. Wang X, Weisleder N, Collet C, Zhou J, Chu Y, Hirata Y, Zhao X, Pan Z, Brotto M, Cheng H, Ma J. Uncontrolled calcium sparks act as a dystrophic signal for mammalian skeletal muscle. Nat Cell Biol 2005;7(5):525-530.
40. Woods CE, Novo D, DiFranco M, Capote J, Vergara JL. Propagation in the transverse tubular system and voltage dependence of calcium release in normal and mdx mouse muscle fibres. J Physiol 2005;568(3):867-880.
41. i and muscle damage in the mdx mouse. J Physiol 2005;562(2):367-380.
42. Campbell KP. Three muscular dystrophies: Loss of cytoskeleton-extracellular matrix linkage. Cell 1995;80(5):675-679.
43. Matsumura K, Tome FM, Ionasescu V, Ervasti JM, Anderson RD, Romero NB, Simon D, Recan D, Kaplan JC, Fardeau M, Campbell KP. Deficiency of dystrophin-associated proteins in Duchenne muscular dystrophy patients lacking COOH-terminal domains of dystrophin. J Clin Invest 1993;92(2):866-871.
44. Straub V, Campbell KP. Muscular dystrophies and the dystrophin-glycoprotein complex. Curr Opin Neurol 1997;10(2):168-175.
45. Emery AE. The muscular dystrophies. Lancet 2002;359(9307):687-695.
46. Finsterer J, Stollberger C. The heart in human dystrophinopathies. Cardiology 2003;99(1):1-19.
47. Ishizaki M, Suga T, Kimura E, Shiota T, Kawano R, Uchida Y, Uchino K, Yamashita S, Maeda Y, Uchino M. Mdx respiratory impairment following fibrosis of the diaphragm. Neuromuscul Disord 2008;18(4):342-348.
48. Laws N, Hoey A. Progression of kyphosis in mdx mice. J Appl Physiol 2004;97(5):1970-1977.
49. Rideau Y, Jankowski LW, Grellet J. Respiratory function in the muscular dystrophies. Muscle Nerve 1981;4(2):155-164.
50. Miyoshi K. Echocardiographic evaluation of fibrous replacement in the myocardium of patients with Duchenne muscular dystrophy. Br Heart J 1991;66(6):452-455.
51. Blake DJ, Weir A, Newey SE, Davies KE. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev 2002;82(2):291-329.
52. Baker MS, Austin L. The pathological damage in Duchenne muscular dystrophy may be due to increased intracellular OXY-radical generation caused by the absence of dystrophin and subsequent alterations in Ca2+ metabolism. Med Hypotheses 1989;29(3):187-193.
53. Fong PY, Turner PR, Denetclaw WF, Steinhardt RA. Increased activity of calcium leak channels in myotubes of Duchenne human and mdx mouse origin. Science 1990;250(4981):673-676.
54. Turner PR, Fong PY, Denetclaw WF, Steinhardt RA. Increased calcium influx in dystrophic muscle. J Cell Biol 1991;115(6):1701-1712.
55. Pardo JV, Siliciano JD, Craig SW. Vinculin is a component of an extensive network of myofibril-sarcolemma attachment regions in cardiac muscle fibers. J Cell Biol 1983;97(4):1081-1088.
56. Pardo JV, Siliciano JD, Craig SW. A vinculin-containing cortical lattice in skeletal muscle: Transverse lattice elements ("costameres") mark sites of attachment between myofibrils and sarcolemma. Proc Natl Acad Sci USA 1983;80(4):1008-1012.
57. Danowski BA, Imanaka-Yoshida K, Sanger JM, Sanger JW. Costameres are sites of force transmission to the substratum in adult rat cardiomyocytes. J Cell Biol 1992;118(6):1411-1420.
58. Deconinck N, Dan B. Pathophysiology of duchenne muscular dystrophy: Current hypotheses. Pediatr Neurol 2007;36(1):1-7.
59. Straub V, Bittner RE, Leger JJ, Voit T. Direct visualization of the dystrophin network on skeletal muscle fiber membrane. J Cell Biol 1992;119(5):1183-1191.
60. Street SF. Lateral transmission of tension in frog myofibers: A myofibrillar network and transverse cytoskeletal connections are possible transmitters. J Cell Physiol 1983;114(3):346-364.
61. Ozawa E. Our trails and trials in the subsarcolemmal cytoskeleton network and muscular dystrophy researches in the dystrophin era. Proc Jpn Acad Ser B Phys Biol Sci 2010;86(8):798-821.
62. Allen DG, Whitehead NP. Duchenne muscular dystrophy-What causes the increased membrane permeability in skeletal muscle? Int J Biochem Cell Biol 2011;43(3):290-294.
63. Ascah A, Khairallah M, Daussin F, Bourcier-Lucas C, Godin R, Allen BG, Petrof BJ, Des Rosiers C, Burelle Y. Stress-induced opening of the permeability transition pore in the dystrophin-deficient heart is attenuated by acute treatment with sildenafil. Am J Physiol Heart Circ Physiol 2011;300(1):H144-H153.
64. Pastoret C, Sebille A. Further aspects of muscular dystrophy in mdx mice. Neuromuscul Disord 1993;3(5-6):471-475.
65. Pastoret C, Sebille A. mdx mice show progressive weakness and muscle deterioration with age. J Neurol Sci 1995;129(2):97-105.
66. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008;214(2):199-210.
67. Alvarez K, Fadic R, Brandan E. Augmented synthesis and differential localization of heparan sulfate proteoglycans in Duchenne muscular dystrophy. J Cell Biochem 2002;85(4):703-713.
68. Fadic R, Mezzano V, Alvarez K, Cabrera D, Holmgren J, Brandan E. Increase in decorin and biglycan in Duchenne muscular dystrophy: Role of fibroblasts as cell source of these proteoglycans in the disease. J Cell Mol Med 2006;10(3):758-769.
69. Mezzano V, Cabrera D, Vial C, Brandan E. Constitutively activated dystrophic muscle fibroblasts show a paradoxical response to TGF-β and CTGF/CCN2. J Cell Commun Signal 2007;1(3-4):205-217.
70. Zhou L, Lu H. Targeting fibrosis in Duchenne muscular dystrophy. J Neuropathol Exp Neurol 2010;69(8):771-776.
71. Sun G, Haginoya K, Dai H, Chiba Y, Uematsu M, Hino-Fukuyo N, Onuma A, Iinuma K, Tsuchiya S. Intramuscular renin-angiotensin system is activated in human muscular dystrophy. J Neurol Sci 2009;280(1-2):40-48.
72. Cabello-Verrugio C, Acuna MJ, Morales MG, Becerra A, Simon F, Brandan E. Fibrotic response induced by angiotensin-II requires NAD(P)H oxidase-induced reactive oxygen species (ROS) in skeletal muscle cells. Biochem Biophys Res Commun 2011;410(3):665-670.
73. Xie S, Sukkar MB, Issa R, Oltmanns U, Nicholson AG, Chung KF. Regulation of TGF-β1-induced connective tissue growth factor expression in airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2005;288(1):L68-L76.
74. Daniels A, Van Bilsen M, Goldschmeding R, Van Der Vusse GJ, Van Nieuwenhoven FA. Connective tissue growth factor and cardiac fibrosis. Acta Physiol Scand 2009;195(3):321-338.
75. Leask A. Potential therapeutic targets for cardiac fibrosis. Circ Res 2010;106(11):1675-1680.
76. Au CG, Butler TL, Sherwood MC, Egan JR, North KN, Winlaw DS. Increased connective tissue growth factor associated with cardiac fibrosis in the mdx mouse model of dystrophic cardiomyopathy. Int J Exp Pathol 2011;92(1):57-65.
77. Sun G, Haginoya K, Wu Y, Chiba Y, Nakanishi T, Onuma A, Sato Y, Takigawa M, Iinuma K, Tsuchiya S. Connective tissue growth factor is overexpressed in muscles of human muscular dystrophy. J Neurol Sci 2008;267(1-2):48-56.
78. Morales MG, Cabello-Verrugio C, Santander C, Cabrera D, Goldschmeding R, Brandan E. CTGF/CCN-2 over-expression can directly induce features of skeletal muscle dystrophy. J Pathol 2011;225(4):490-501.
79. Cabello-Verrugio C, Morales MG, Cabrera D, Vio CP, Brandan E. Angiotensin II receptor type 1 blockade decreases CTGF/CCN2-mediated damage and fibrosis in normal and dystrophic skeletal muscles. J Cell Mol Med 2012;16(4):752-764.
80. Bernasconi P, Torchiana E, Confalonieri P, Brugnoni R, Barresi R, Mora M, Cornelio F, Morandi L, Mantegazza R. Expression of transforming growth factor-β 1 in dystrophic patient muscles correlates with fibrosis. Pathogenetic role of a fibrogenic cytokine. J Clin Invest 1995;96(2):1137-1144.
81. Ishitobi M, Haginoya K, Zhao Y, Ohnuma A, Minato J, Yanagisawa T, Tanabu M, Kikuchi M, Iinuma K. Elevated plasma levels of transforming growth factor β1 in patients with muscular dystrophy. Neuroreport 2000;11(18):4033-4035.
82. Porter JD, Merriam AP, Leahy P, Gong B, Khanna S. Dissection of temporal gene expression signatures of affected and spared muscle groups in dystrophin-deficient (mdx) mice. Hum Mol Genet 2003;12(15):1813-1821.
83. Brooke MH, Fenichel GM, Griggs RC, Mendell JR, Moxley R, Florence J, King WM, Pandya S, Robison J, Schierbecker J, Signore L, Miller JP, Gilder BF, Kaiser KK, Mandel S, Arfken C. Duchenne muscular dystrophy: Patterns of clinical progression and effects of supportive therapy. Neurology 1989;39(4):475-481.
84. Bach JR, Ishikawa Y, Kim H. Prevention of pulmonary morbidity for patients with Duchenne muscular dystrophy. Chest 1997;112(4):1024-1028.
85. Inkley SR, Oldenburg FC, Vignos PJ, Jr. Pulmonary function in Duchenne muscular dystrophy related to stage of disease. Am J Med 1974;56(3):297-306.
86. Mukoyama M, Kondo K, Hizawa K, Nishitani H. Life spans of Duchenne muscular dystrophy patients in the hospital care program in Japan. J Neurol Sci 1987;81(2-3):155-158.
87. Rideau Y, Gatin G, Bach J, Gines G. Prolongation of life in Duchenne's muscular dystrophy. Acta Neurol (Napoli) 1983;5(2):118-124.
88. Eagle M, Baudouin SV, Chandler C, Giddings DR, Bullock R, Bushby K. Survival in Duchenne muscular dystrophy: Improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord 2002;12(10):926-929.
89. Finder JD, Birnkrant D, Carl J, Farber HJ, Gozal D, Iannaccone ST, Kovesi T, Kravitz RM, Panitch H, Schramm C, Schroth M, Sharma G, Sievers L, Silvestri JM, Sterni L. Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus statement. Am J Respir Crit Care Med 2004;170(4):456-465.
90. Jeppesen J, Green A, Steffensen BF, Rahbek J. The Duchenne muscular dystrophy population in Denmark, 1977-2001: Prevalence, incidence and survival in relation to the introduction of ventilator use. Neuromuscul Disord 2003;13(10):804-812.
91. Konagaya M, Sakai M, Wakayama T, Kimura S, Kuru S, Yasuma F. Effect of intermittent positive pressure ventilation on life-span and causes of death in Duchenne muscular dystrophy. Rinsho Shinkeigaku 2005;45(9):643-646.
92. Toussaint M, Steens M, Wasteels G, Soudon P. Diurnal ventilation via mouthpiece: Survival in end-stage Duchenne patients. Eur Respir J 2006;28(3):549-555.
93. Yasuma F, Konagaya M, Sakai M, Kuru S, Kawamura T. A new lease on life for patients with Duchenne muscular dystrophy in Japan. Am J Med 2004;117(5):363.
94. Ishikawa Y, Bach JR, Minami R. Cardioprotection for Duchenne's muscular dystrophy. Am Heart J 1999;137(5):895-902.
95. Ogata H, Ishikawa Y, Minami R. Beneficial effects of β-blockers and angiotensin-converting enzyme inhibitors in Duchenne muscular dystrophy. J Cardiol 2009;53(1):72-78.
96. Ramaciotti C, Heistein LC, Coursey M, Lemler MS, Eapen RS, Iannaccone ST, Scott WA. Left ventricular function and response to enalapril in patients with Duchenne muscular dystrophy during the second decade of life. Am J Cardiol 2006;98(6):825-827.
97. Viollet L, Thrush PT, Flanigan KM, Mendell JR, Allen HD. Effects of angiotensin-converting enzyme inhibitors and/or β blockers on the cardiomyopathy in Duchenne muscular dystrophy. Am J Cardiol 2012;110(1):98-102.
98. Frankel KA, Rosser RJ. The pathology of the heart in progressive muscular dystrophy: Epimyocardial fibrosis. Hum Pathol 1976;7(4):375-386.
99. Lanza GA, Dello Russo A, Giglio V, De Luca L, Messano L, Santini C, Ricci E, Damiani A, Fumagalli G, De Martino G, Mangiola F, Bellocci F. Impairment of cardiac autonomic function in patients with Duchenne muscular dystrophy: Relationship to myocardial and respiratory function. Am Heart J 2001;141(5):808-812.
100. McDonald CM, Abresch RT, Carter GT, Fowler WM, Jr., Johnson ER, Kilmer DD, Sigford BJ. Profiles of neuromuscular diseases. Duchenne muscular dystrophy. Am J Phys Med Rehabil 1995;74(5 Suppl):S70-92.
101. Melacini P, Vianello A, Villanova C, Fanin M, Miorin M, Angelini C, Dalla Volta S. Cardiac and respiratory involvement in advanced stage Duchenne muscular dystrophy. Neuromuscul Disord 1996;6(5):367-376.
102. Perloff JK, de Leon AC, Jr., O'Doherty D. The cardiomyopathy of progressive muscular dystrophy. Circulation 1966;33(4):625-648.
103. Ameen V, Robson LG. Experimental models of Duchenne muscular dystrophy: Relationship with cardiovascular disease. Open Cardiovasc Med J 2010;4:265-277.
104. Ramaciotti C, Iannaccone ST, Scott WA. Myocardial cell damage in Duchenne muscular dystrophy. Pediatr Cardiol 2003;24(5):503-506.
105. Gozal D, Thiriet P. Respiratory muscle training in neuromuscular disease: Long-term effects on strength and load perception. Med Sci Sports Exerc 1999;31(11):1522-1527.
106. Howard RS, Wiles CM, Hirsch NP, Spencer GT. Respiratory involvement in primary muscle disorders: Assessment and management. Q J Med 1993;86(3):175-189.
107. Lo Mauro A, D'Angelo MG, Romei M, Motta F, Colombo D, Comi GP, Pedotti A, Marchi E, Turconi AC, Bresolin N, Aliverti A. Abdominal volume contribution to tidal volume as an early indicator of respiratory impairment in Duchenne muscular dystrophy. Eur Respir J 2010;35(5):1118-1125.
108. Khan Y, Heckmatt JZ. Obstructive apnoeas in Duchenne muscular dystrophy. Thorax 1994;49(2):157-161.
109. Barbe F, Quera-Salva MA, McCann C, Gajdos P, Raphael JC, de Lattre J, Agusti AG. Sleep-related respiratory disturbances in patients with Duchenne muscular dystrophy. Eur Respir J 1994;7(8):1403-1408.
110. Phillips MF, Smith PE, Carroll N, Edwards RH, Calverley PM. Nocturnal oxygenation and prognosis in Duchenne muscular dystrophy. Am J Respir Crit Care Med 1999;160(1):198-202.
111. De Bruin PF, Ueki J, Bush A, Khan Y, Watson A, Pride NB. Diaphragm thickness and inspiratory strength in patients with Duchenne muscular dystrophy. Thorax 1997;52(5):472-475.
112. Fukunaga H, Sonoda Y, Atsuchi H, Osame M. Respiratory failure and its care in Duchenne muscular dystrophy. Rinsho Shinkeigaku 1991;31(2):154-158.
113. Phillips MF, Quinlivan RC, Edwards RH, Calverley PM. Changes in spirometry over time as a prognostic marker in patients with Duchenne muscular dystrophy. Am J Respir Crit Care Med 2001;164(12):2191-2194.
114. Hukins CA, Hillman DR. Daytime predictors of sleep hypoventilation in Duchenne muscular dystrophy. Am J Respir Crit Care Med 2000;161(1):166-170.
115. Smith PE, Calverley PM, Edwards RH. Hypoxemia during sleep in Duchenne muscular dystrophy. Am Rev Respir Dis 1988;137(4):884-888.
116. Tangsrud SE, Petersen IL, LØDrup Carlsen KC, Carlsen KH. Lung function in children with Duchenne's muscular dystrophy. Respir Med 2001;95(11):898-903.
117. Gayraud J, Ramonatxo M, Rivier F, Humberclaude V, Petrof B, Matecki S. Ventilatory parameters and maximal respiratory pressure changes with age in Duchenne muscular dystrophy patients. Pediatr Pulmonol 2010;45(6):552-559.
118. De Troyer A, Kelly S, Macklem PT, Zin WA. Mechanics of intercostal space and actions of external and internal intercostal muscles. J Clin Invest 1985;75(3):850-857.
119. Estenne M, Gevenois PA, Kinnear W, Soudon P, Heilporn A, De Troyer A. Lung volume restriction in patients with chronic respiratory muscle weakness: The role of microatelectasis. Thorax 1993;48(7):698-701.
120. Lynn DJ, Woda RP, Mendell JR. Respiratory dysfunction in muscular dystrophy and other myopathies. Clin Chest Med 1994;15(4):661-674.
121. Smith PE, Calverley PM, Edwards RH, Evans GA, Campbell EJ. Practical problems in the respiratory care of patients with muscular dystrophy. N Engl J Med 1987;316(19):1197-1205.
122. Baydur A, Gilgoff I, Prentice W, Carlson M, Fischer DA. Decline in respiratory function and experience with long-term assisted ventilation in advanced Duchenne's muscular dystrophy. Chest 1990;97(4):884-889.
123. Beck J, Weinberg J, Hamnegård C-H, Spahija J, Olofson J, Grimby G, Sinderby C. Diaphragmatic function in advanced Duchenne muscular dystrophy. Neuromuscul Disord 2006;16(3):161-167.
124. De Bruin PF, Ueki J, Bush A, Y Manzur A, Watson A, Pride NB. Inspiratory flow reserve in boys with Duchenne muscular dystrophy. Pediatr Pulmonol 2001;31(6):451-457.
125. Guell MR, Avendano M, Fraser J, Goldstein R. Pulmonary and nonpulmonary alterations in Duchenne muscular dystrophy. Arch Bronconeumol 2007;43(10):557-561.
126. Park JH, Kang SW, Lee SC, Choi WA, Kim DH. How respiratory muscle strength correlates with cough capacity in patients with respiratory muscle weakness. Yonsei Med J 2010;51(3):392-397.
127. Marques MJ, Ferretti R, Vomero VU, Minatel E, Neto HS. Intrinsic laryngeal muscles are spared from myonecrosis in the mdx mouse model of Duchenne muscular dystrophy. Muscle Nerve 2007;35(3):349-353.
128. Smythe GM. Dystrophic pathology in the intrinsic and extrinsic laryngeal muscles in the mdx mouse. J Otolaryngol Head Neck Surg 2009;38(3):323-336.
129. Caress JB, Kothari MJ, Bauer SB, Shefner JM. Urinary dysfunction in Duchenne muscular dystrophy. Muscle Nerve 1996;19(7):819-822.
130. Khurana TS, Prendergast RA, Alameddine HS, Tome FM, Fardeau M, Arahata K, Sugita H, Kunkel LM. Absence of extraocular muscle pathology in Duchenne's muscular dystrophy: Role for calcium homeostasis in extraocular muscle sparing. J Exp Med 1995;182(2):467-475.
131. Kaminski HJ, al-Hakim M, Leigh RJ, Katirji MB, Ruff RL. Extraocular muscles are spared in advanced Duchenne dystrophy. Ann Neurol 1992;32(4):586-588.
132. Felder E, Bogdanovich S, Rubinstein NA, Khurana TS. Structural details of rat extraocular muscles and three-dimensional reconstruction of the rat inferior rectus muscle and muscle-pulley interface. Vision Res 2005;45(15):1945-1955.
133. Hunter MI, Mohamed JB. Plasma antioxidants and lipid peroxidation products in Duchenne muscular dystrophy. Clin Chim Acta 1986;155(2):123-131.
134. Wehling M, Stull JT, McCabe TJ, Tidball JG. Sparing of mdx extraocular muscles from dystrophic pathology is not attributable to normalized concentration or distribution of neuronal nitric oxide synthase. Neuromuscul Disord 1998;8(1):22-29.
135. Ragusa RJ, Chow CK, Porter JD. Oxidative stress as a potential pathogenic mechanism in an animal model of Duchenne muscular dystrophy. Neuromuscul Disord 1997;7(6-7):379-386.
136. Ragusa RJ, Chow CK, St. Clair DK, Porter JD. Extraocular, limb and diaphragm muscle group-specific antioxidant enzyme activity patterns in control and mdx mice. J Neurol Sci 1996;139(2):180-186.
137. Porter JD, Merriam AP, Khanna S, Andrade FH, Richmonds CR, Leahy P, Cheng G, Karathanasis P, Zhou X, Kusner LL, Adams ME, Willem M, Mayer U, Kaminski HJ. Constitutive properties, not molecular adaptations, mediate extraocular muscle sparing in dystrophic mdx mice. FASEB J 2003;17(8):893-895.
138. Zeiger U, Mitchell CH, Khurana TS. Superior calcium homeostasis of extraocular muscles. Exp Eye Res 2010;91(5):613-622.
139. 2+ sinks in rat extraocular muscles: A novel regulatory influence on contractile function and metabolism. Invest Ophthalmol Vis Sci 2005;46(12):4541-4547.
140. Fischer MD. Expression profiling reveals metabolic and structural components of extraocular muscles. Physiol Genomics 2002;9(2):71-84.
141. Fischer MD, Budak MT, Bakay M, Gorospe JR, Kjellgren D, Pedrosa-Domellof F, Hoffman EP, Khurana TS. Definition of the unique human extraocular muscle allotype by expression profiling. Physiol Genomics 2005;22(3):283-291.
142. Khanna S, Richmonds CR, Kaminski HJ, Porter JD. Molecular organization of the extraocular muscle neuromuscular junction: Partial conservation of and divergence from the skeletal muscle prototype. Invest Ophthalmol Vis Sci 2003;44(5):1918-1926.
143. Porter JD, Khanna S, Kaminski HJ, Rao JS, Merriam AP, Richmonds CR, Leahy P, Li J, Andrade FH. Extraocular muscle is defined by a fundamentally distinct gene expression profile. Proc Natl Acad Sci USA 2001;98(21):12062-12067.
144. Greener MJ, Roberts RG. Conservation of components of the dystrophin complex in Drosophila. FEBS Lett 2000;482(1-2):13-18.
145. Jin H, Tan S, Hermanowski J, Bohm S, Pacheco S, McCauley J, Greener M, Hinits Y, Hughes S, Sharpe P, Roberts R. The dystrotelin, dystrophin and dystrobrevin superfamily: New paralogues and old isoforms. BMC Genomics 2007;8(1):19.
146. Bulfield G, Siller WG, Wight PA, Moore KJ. X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci USA 1984;81(4):1189-1192.
147. Ryder-Cook AS, Sicinski P, Thomas K, Davies KE, Worton RG, Barnard EA, Darlison MG, Barnard PJ. Localization of the mdx mutation within the mouse dystrophin gene. EMBO J 1988;7(10):3017-3021.
148. Cooper BJ, Winand NJ, Stedman H, Valentine BA, Hoffman EP, Kunkel LM, Scott M-O, Fischbeck KH, Kornegay JN, Avery RJ, Williams JR, Schmickel RD, Sylvester JE. The homologue of the Duchenne locus is defective in X-linked muscular dystrophy of dogs. Nature 1988;334(6178):154-156.
149. Bassett DI, Currie PD. The zebrafish as a model for muscular dystrophy and congenital myopathy. Hum Mol Genet 2003;12 Spec No 2:R265-R270.
150. Bessou C, Giugia JB, Franks CJ, Holden-Dye L, Segalat L. Mutations in the Caenorhabditis elegans dystrophin-like gene dys-1 lead to hyperactivity and suggest a link with cholinergic transmission. Neurogenetics 1998;2(1):61-72.
151. Neuman S, Kaban A, Volk T, Yaffe D, Nudel U. The dystrophin/utrophin homologues in Drosophila and in sea urchin. Gene 2001;263(1-2):17-29.
152. Roberts DB, Mulvany WJ, Dwek RA, Rudd PM. Mutant analysis reveals an alternative pathway for N-linked glycosylation in Drosophila melanogaster. Eur J Biochem 1998;253(2):494-498.
153. Shcherbata HR, Yatsenko AS, Patterson L, Sood VD, Nudel U, Yaffe D, Baker D, Ruohola-Baker H. Dissecting muscle and neuronal disorders in a Drosophila model of muscular dystrophy. EMBO J 2007;26(2):481-493.
154. Im WB, Phelps SF, Copen EH, Adams EG, Slightom JL, Chamberlain JS. Differential expression of dystrophin isoforms in strains of mdx mice with different mutations. Hum Mol Genet 1996;5(8):1149-1153.
155. Araki E, Nakamura K, Nakao K, Kameya S, Kobayashi O, Nonaka I, Kobayashi T, Katsuki M. Targeted disruption of exon 52 in the mouse dystrophin gene induced muscle degeneration similar to that observed in Duchenne muscular dystrophy. Biochem Biophys Res Commun 1997;238(2):492-497.
156. Anderson JE, Garrett K, Moor A, McIntosh L, Penner K. Dystrophy and myogenesis in mdx diaphragm muscle. Muscle Nerve 1998;21(9):1153-1165.
157. Chamberlain JS, Metzger J, Reyes M, Townsend D, Faulkner JA. Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma. FASEB J 2007;21(9):2195-2204.
158. Pastoret C, Sebille A. Age-related differences in regeneration of dystrophic (mdx) and normal muscle in the mouse. Muscle Nerve 1995;18(10):1147-1154.
159. McGeachie JK, Grounds MD, Partridge TA, Morgan JE. Age-related changes in replication of myogenic cells in mdx mice: Quantitative autoradiographic studies. J Neurol Sci 1993;119(2):169-179.
160. Dangain J, Vrbova G. Muscle development in mdx mutant mice. Muscle Nerve 1984;7(9):700-704.
161. Tanabe Y, Esaki K, Nomura T. Skeletal muscle pathology in X chromosome-linked muscular dystrophy mouse. Acta Neuropathol (Berl) 1986;69(1):91-95.
162. Stedman HH, Sweeney HL, Shrager JB, Maguire HC, Panettieri RA, Petrof B, Narusawa M, Leferovich JM, Sladky JT, Kelly AM. The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature 1991;352(6335):536-539.
163. Granchelli JA, Pollina C, Hudecki MS. Pre-clinical screening of drugs using the mdx mouse. Neuromuscul Disord 2000;10(4-5):235-239.
164. Hudecki MS, Pollina CM, Granchelli JA, Daly MK, Byrnes T, Wang JC, Hsiao JC. Strength and endurance in the therapeutic evaluation of prednisolone-treated mdx mice. Res Commun Chem Pathol Pharmacol 1993;79(1):45-60.
165. Hara H, Nolan PM, Scott MO, Bucan M, Wakayama Y, Fischbeck KH. Running endurance abnormality in mdx mice. Muscle Nerve 2002;25(2):207-211.
166. Tinsley JM, Blake DJ, Roche A, Fairbrother U, Riss J, Byth BC, Knight AE, Kendrick-Jones J, Suthers GK, Love DR, Edwards YH, Davies KE. Primary structure of dystrophin-related protein. Nature 1992;360(6404):591-593.
167. Khurana TS, Watkins SC, Chafey P, Chelly J, Tome FM, Fardeau M, Kaplan JC, Kunkel LM. Immunolocalization and developmental expression of dystrophin related protein in skeletal muscle. Neuromuscul Disord 1991;1(3):185-194.
168. Ohlendieck K, Ervasti JM, Matsumura K, Kahl SD, Leveille CJ, Campbell KP. Dystrophin-related protein is localized to neuromuscular junctions of adult skeletal muscle. Neuron 1991;7(3):499-508.
169. Pons F, Augier N, Leger JO, Robert A, Tome FM, Fardeau M, Voit T, Nicholson LV, Mornet D, Leger JJ. A homologue of dystrophin is expressed at the neuromuscular junctions of normal individuals and DMD patients, and of normal and mdx mice. Immunological evidence. FEBS Lett 1991;282(1):161-165.
170. Matsumura K, Ervasti JM, Ohlendieck K, Kahl SD, Campbell KP. Association of dystrophin-related protein with dystrophin-associated proteins in mdx mouse muscle. Nature 1992;360(6404):588-591.
171. Mizuno Y, Nonaka I, Hirai S, Ozawa E. Reciprocal expression of dystrophin and utrophin in muscles of Duchenne muscular dystrophy patients, female DMD-carriers and control subjects. J Neurol Sci 1993;119(1):43-52.
172. Pons F, Robert A, Marini JF, Leger JJ. Does utrophin expression in muscles of mdx mice during postnatal development functionally compensate for dystrophin deficiency? J Neurol Sci 1994;122(2):162-170.
173. Grady RM, Teng H, Nichol MC, Cunningham JC, Wilkinson RS, Sanes JR. Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: A model for Duchenne muscular dystrophy. Cell 1997;90(4):729-738.
174. Deconinck AE, Rafael JA, Skinner JA, Brown SC, Potter AC, Metzinger L, Watt DJ, Dickson JG, Tinsley JM, Davies KE. Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell 1997;90(4):717-727.
175. Zhou L, Rafael-Fortney JA, Huang P, Zhao XS, Cheng G, Zhou X, Kaminski HJ, Liu L, Ransohoff RM. Haploinsufficiency of utrophin gene worsens skeletal muscle inflammation and fibrosis in mdx mice. J Neurol Sci 2008;264(1-2):106-111.
176. van Putten M, Kumar D, Hulsker M, Hoogaars WM, Plomp JJ, van Opstal A, van Iterson M, Admiraal P, van Ommen GJ, t Hoen PA, Aartsma-Rus A. Comparison of skeletal muscle pathology and motor function of dystrophin and utrophin deficient mouse strains. Neuromuscul Disord 2012;22(5):406-417.
177. Sacco A, Mourkioti F, Tran R, Choi J, Llewellyn M, Kraft P, Shkreli M, Delp S, Pomerantz JH, Artandi SE, Blau HM. Short telomeres and stem cell exhaustion model Duchenne muscular dystrophy in mdx/mTR mice. Cell 2010;143(7):1059-1071.
178. Chandrasekharan K, Yoon JH, Xu Y, deVries S, Camboni M, Janssen PM, Varki A, Martin PT. A human-specific deletion in mouse Cmah increases disease severity in the mdx model of Duchenne muscular dystrophy. Sci Transl Med 2010;2(42):42ra54.
179. Rooney JE, Welser JV, Dechert MA, Flintoff-Dye NL, Kaufman SJ, Burkin DJ. Severe muscular dystrophy in mice that lack dystrophin and α7 integrin. J Cell Sci 2006;119(Pt 11):2185-2195.
180. Grady RM, Grange RW, Lau KS, Maimone MM, Nichol MC, Stull JT, Sanes JR. Role for α-dystrobrevin in the pathogenesis of dystrophin-dependent muscular dystrophies. Nat Cell Biol 1999;1(4):215-220.
181. Megeney LA, Kablar B, Perry RL, Ying C, May L, Rudnicki MA. Severe cardiomyopathy in mice lacking dystrophin and MyoD. Proc Natl Acad Sci USA 1999;96(1):220-225.
182. Consolino CM, Brooks SV. Susceptibility to sarcomere injury induced by single stretches of maximally activated muscles of mdx mice. J Appl Physiol 2004;96(2):633-638.
183. Dellorusso C, Crawford RW, Chamberlain JS, Brooks SV. Tibialis anterior muscles in mdx mice are highly susceptible to contraction-induced injury. J Muscle Res Cell Motil 2001;22(5):467-475.
184. Friedrich O, Both M, Gillis JM, Chamberlain JS, Fink RH. Mini-dystrophin restores L-type calcium currents in skeletal muscle of transgenic mdx mice. J Physiol 2004;555(Pt 1):251-265.
185. Friedrich O, Both M, Weber C, Schurmann S, Teichmann MD, von Wegner F, Fink RH, Vogel M, Chamberlain JS, Garbe C. Microarchitecture is severely compromised but motor protein function is preserved in dystrophic mdx skeletal muscle. Biophys J 2010;98(4):606-616.
186. 2+ channel function is linked to dystrophin expression in mammalian muscle. PLoS One 2008;3(3):e1762.
187. Lynch GS, Hinkle RT, Chamberlain JS, Brooks SV, Faulkner JA. Force and power output of fast and slow skeletal muscles from mdx mice 6-28 months old. J Physiol 2001;535(Pt 2):591-600.
188. Petrof BJ. The molecular basis of activity-induced muscle injury in Duchenne muscular dystrophy. Mol Cell Biochem 1998;179(1-2):111-123.
189. Anderson JE, Murray L, Barr Award Lecture. Studies of the dynamics of skeletal muscle regeneration: the mouse came back! Biochem Cell Biol 1998;76(1):13-26.
190. Moens P, Baatsen PH, Marechal G. Increased susceptibility of EDL muscles from mdx mice to damage induced by contractions with stretch. J Muscle Res Cell Motil 1993;14(4):446-451.
191. Head SI, Williams DA, Stephenson DG. Abnormalities in structure and function of limb skeletal muscle fibres of dystrophic mdx mice. Proc Biol Sci 1992;248(1322):163-169.
192. Torres LF, Duchen LW. The mutant mdx: Inherited myopathy in the mouse. Morphological studies of nerves, muscles and end-plates. Brain 1987;110(Pt 2):269-299.
193. Schinkel S, Bauer R, Bekeredjian R, Stucka R, Rutschow D, Lochmuller H, Kleinschmidt JA, Katus HA, Muller OJ. Long-term preservation of cardiac structure and function after adeno-associated virus serotype 9-mediated microdystrophin gene transfer in mdx mice. Hum Gene Ther 2012;23(6):566-575.
194. Bostick B, Yue Y, Long C, Duan D. Prevention of dystrophin-deficient cardiomyopathy in twenty-one-month-old carrier mice by mosaic dystrophin expression or complementary dystrophin/utrophin expression. Circ Res 2008;102(1):121-130.
195. Chu V, Otero JM, Lopez O, Sullivan MF, Morgan JP, Amende I, Hampton TG. Electrocardiographic findings in mdx mice: A cardiac phenotype of Duchenne muscular dystrophy. Muscle Nerve 2002;26(4):513-519.
196. Wehling-Henricks M, Jordan MC, Roos KP, Deng B, Tidball JG. Cardiomyopathy in dystrophin-deficient hearts is prevented by expression of a neuronal nitric oxide synthase transgene in the myocardium. Hum Mol Genet 2005;14(14):1921-1933.
197. Nakamura A, Yoshida K, Takeda S, Dohi N, Ikeda S. Progression of dystrophic features and activation of mitogen-activated protein kinases and calcineurin by physical exercise, in hearts of mdx mice. FEBS Lett 2002;520(1-3):18-24.
198. Quinlan JG, Hahn HS, Wong BL, Lorenz JN, Wenisch AS, Levin LS. Evolution of the mdx mouse cardiomyopathy: Physiological and morphological findings. Neuromuscul Disord 2004;14(8-9):491-496.
199. Van Erp C, Loch D, Laws N, Trebbin A, Hoey AJ. Timeline of cardiac dystrophy in 3-18-month-old mdx mice. Muscle Nerve 2010;42(4):504-513.
200. Bia BL, Cassidy PJ, Young ME, Rafael JA, Leighton B, Davies KE, Radda GK, Clarke K. Decreased myocardial nNOS, increased iNOS and abnormal ECGs in mouse models of Duchenne muscular dystrophy. J Mol Cell Cardiol 1999;31(10):1857-1862.
201. 2+ channel by the actin-binding proteins α-actinin and dystrophin. Am J Physiol Cell Physiol 2002;282(6):C1502-1511.
202. Wilding JR, Schneider JE, Sang AE, Davies KE, Neubauer S, Clarke K. Dystrophin- and MLP-deficient mouse hearts: Marked differences in morphology and function, but similar accumulation of cytoskeletal proteins. FASEB J 2005;19(1):79-81.
203. Williams IA, Allen DG. Intracellular calcium handling in ventricular myocytes from mdx mice. Am J Physiol Heart Circ Physiol 2007;292(2):H846-H855.
204. Bostick B, Yue Y, Long C, Marschalk N, Fine DM, Chen J, Duan D. Cardiac expression of a mini-dystrophin that normalizes skeletal muscle force only partially restores heart function in aged mdx mice. Mol Ther 2009;17(2):253-261.
205. Van Erp C, Irwin NG, Hoey AJ. Long-term administration of pirfenidone improves cardiac function in mdx mice. Muscle Nerve 2006;34(3):327-334.
206. Wu B, Moulton HM, Iversen PL, Jiang J, Li J, Li J, Spurney CF, Sali A, Guerron AD, Nagaraju K, Doran T, Lu P, Xiao X, Lu QL. Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc Natl Acad Sci USA 2008;105(39):14814-14819.
207. Yue Y, Skimming JW, Liu M, Strawn T, Duan D. Full-length dystrophin expression in half of the heart cells ameliorates β-isoproterenol-induced cardiomyopathy in mdx mice. Hum Mol Genet 2004;13(15):1669-1675.
208. Zhang W, ten Hove M, Schneider JE, Stuckey DJ, Sebag-Montefiore L, Bia BL, Radda GK, Davies KE, Neubauer S, Clarke K. Abnormal cardiac morphology, function and energy metabolism in the dystrophic mdx mouse: An MRI and MRS study. J Mol Cell Cardiol 2008;45(6):754-760.
209. Rouger K, Le Cunff M, Steenman M, Potier MC, Gibelin N, Dechesne CA, Leger JJ. Global/temporal gene expression in diaphragm and hindlimb muscles of dystrophin-deficient (mdx) mice. Am J Physiol Cell Physiol 2002;283(3):C773-C784.
210. Krüger J, Kunert-Keil C, Bisping F, Brinkmeier H. Transient receptor potential cation channels in normal and dystrophic mdx muscle. Neuromuscul Disord 2008;18(6):501-513.
211. Gosselin LE, Barkley JE, Spencer MJ, McCormick KM, Farkas GA. Ventilatory dysfunction in mdx mice: Impact of tumor necrosis factor-α deletion. Muscle Nerve 2003;28(3):336-343.
212. 2 breathing on cellular adaptation of mdx mouse diaphragm. Neuromuscul Disord 2005;15(6):427-436.
213. Mosqueira MM, Baby SM, Budak M, Bogdanovich S, Willmann G, Lahiri S, Khurana T. Role of hypoxia in muscle function and muscular dystrophy. FASEB J 2008;22(1_MeetingAbstracts):1224.12.
214. Personius KE, Sawyer RP. Variability and failure of neurotransmission in the diaphragm of mdx mice. Neuromuscul Disord 2006;16(3):168-177.
215. ++ at rest and after cholinergic stimulus is increased in cultured muscle cells from Duchenne muscular dystrophy patients. Neurology 1988;38(3):476-480.
216. Bodensteiner JB, Engel AG. Intracellular calcium accumulation in Duchenne dystrophy and other myopathies: A study of 567, 000 muscle fibers in 114 biopsies. Neurology 1978;28(5):439-446.
217. 2+ entry in dystrophic skeletal muscle fibers. J Cell Sci 2006;119(Pt 18):3733-3742.
218. Bradley WG, Fulthorpe JJ. Studies of sarcolemmal integrity in myopathic muscle. Neurology 1978;28(7):670-677.
219. Franco A, Jr., Lansman JB. Calcium entry through stretch-inactivated ion channels in mdx myotubes. Nature 1990;344(6267):670-673.
220. 2+ sparks via mechanosensitive channels is disrupted in dystrophin deficient muscle but restored by mini-dystrophin expression. PLoS One 2008;3(11):e3644.
221. Robert V, Massimino ML, Tosello V, Marsault R, Cantini M, Sorrentino V, Pozzan T. Alteration in calcium handling at the subcellular level in mdx myotubes. J Biol Chem 2001;276(7):4647-4651.
222. Turner PR, Westwood T, Regen CM, Steinhardt RA. Increased protein degradation results from elevated free calcium levels found in muscle from mdx mice. Nature 1988;335(6192):735-738.
223. Dowling P, Doran P, Ohlendieck K. Drastic reduction of sarcalumenin in Dp427 (dystrophin of 427 kDa)-deficient fibres indicates that abnormal calcium handling plays a key role in muscular dystrophy. Biochem J 2004;379(Pt 2):479-488.
224. Goonasekera SA, Lam CK, Millay DP, Sargent MA, Hajjar RJ, Kranias EG, Molkentin JD. Mitigation of muscular dystrophy in mice by SERCA overexpression in skeletal muscle. J Clin Invest 2011;121(3):1044-1052.
225. Morine KJ, Sleeper MM, Barton ER, Sweeney HL. Overexpression of SERCA1a in the mdx diaphragm reduces susceptibility to contraction-induced damage. Hum Gene Ther 2010;21(12):1735-1739.
226. Dowling P, Lohan J, Ohlendieck K. Comparative analysis of Dp427-deficient mdx tissues shows that the milder dystrophic phenotype of extraocular and toe muscle fibres is associated with a persistent expression of β-dystroglycan. Eur J Cell Biol 2003;82(5):222-230.
227. 2+-ATPase and calsequestrin are overexpressed in spared intrinsic laryngeal muscles of dystrophin-deficient mdx mice. Muscle Nerve 2009;39(5):609-615.
228. Culligan K, Banville N, Dowling P, Ohlendieck K. Drastic reduction of calsequestrin-like proteins and impaired calcium binding in dystrophic mdx muscle. J Appl Physiol 2002;92(2):435-445.
229. Spencer MJ, Mellgren RL. Overexpression of a calpastatin transgene in mdx muscle reduces dystrophic pathology. Hum Mol Genet 2002;11(21):2645-2655.
230. 2+ signalling and reactive oxygen species-generating pathways. Cardiovasc Res 2008;77(4):766-773.
231. 2+ signals in stressed mdx dystrophic skeletal muscle fibers. Pflugers Arch 2009;458(5):915-928.
232. 2+ signals produced by osmotic stress in mouse skeletal muscle fibres. J Physiol 2008;586(1):197-210.
233. Ullrich ND, Fanchaouy M, Gusev K, Shirokova N, Niggli E. Hypersensitivity of excitation-contraction coupling in dystrophic cardiomyocytes. Am J Physiol Heart Circ Physiol 2009;297(6):H1992-H2003.
234. Prosser BL, Ward CW, Lederer WJ. X-ROS signaling: Rapid mechano-chemo transduction in heart. Science 2011;333(6048):1440-1445.
235. 2+ entry into mouse skeletal muscle fibres. J Physiol 2001;533(Pt 1):185-199.
236. 2+ entry and the inositol trisphosphate receptor. Proc Natl Acad Sci USA 2003;100(5):2941-2944.
237. Stiber J, Hawkins A, Zhang ZS, Wang S, Burch J, Graham V, Ward CC, Seth M, Finch E, Malouf N, Williams RS, Eu JP, Rosenberg P. STIM1 signalling controls store-operated calcium entry required for development and contractile function in skeletal muscle. Nat Cell Biol 2008;10(6):688-697.
238. 2+ influx. Curr Biol 2005;15(13):1235-1241.
239. Soboloff J, Spassova MA, Tang XD, Hewavitharana T, Xu W, Gill DL. Orai1 and STIM reconstitute store-operated calcium channel function. J Biol Chem 2006;281(30):20661-20665.
240. Venkatachalam K, van Rossum DB, Patterson RL, Ma HT, Gill DL. The cellular and molecular basis of store-operated calcium entry. Nat Cell Biol 2002;4(11):E263-E272.
241. 2+ store to the plasma membrane. Nature 2005;437(7060):902-905.
242. Vig M, Beck A, Billingsley JM, Lis A, Parvez S, Peinelt C, Koomoa DL, Soboloff J, Gill DL, Fleig A, Kinet JP, Penner R. CRACM1 multimers form the ion-selective pore of the CRAC channel. Curr Biol 2006;16(20):2073-2079.
243. 2+ entry in dystrophic mdx mouse muscle. Am J Physiol Cell Physiol 2010;299(1):C42-C50.
244. Venkatachalam K, Montell C. TRP channels. Annu Rev Biochem 2007;76:387-417.
245. Brinkmeier H. TRP channels in skeletal muscle: Gene expression, function and implications for disease. In: Islam MS, Ed. Transient Receptor Potential Channels, Vol. 704, Advances in Experimental Medicine and Biology. Netherlands: Springer; 2011. p 749-758.
246. Montell C. The TRP superfamily of cation channels. Sci STKE 2005;2005(272):re3.
247. Montell C, Birnbaumer L, Flockerzi V. The TRP channels, a remarkably functional family. Cell 2002;108(5):595-598.
248. 2+ influx and muscle fatigue. Pflügers Archiv 2011;461(1):115-122.
249. Kunert-Keil C, Bisping F, Krüger J, Brinkmeier H. Tissue-specific expression of TRP channel genes in the mouse and its variation in three different mouse strains. BMC Genomics 2006;7:159.
250. 2+ influx via TRPV2 ameliorates muscular dystrophy in animal models. Hum Mol Genet 2009;18(5):824-834.
251. Beech DJ, Muraki K, Flemming R. Non-selective cationic channels of smooth muscle and the mammalian homologues of Drosophila TRP. J Physiol 2004;559(Pt 3):685-706.
252. Clapham DE. TRP channels as cellular sensors. Nature 2003;426(6966):517-524.
253. Clapham DE, Runnels LW, Strubing C. The TRP ion channel family. Nat Rev Neurosci 2001;2(6):387-396.
254. Maroto R, Raso A, Wood TG, Kurosky A, Martinac B, Hamill OP. TRPC1 forms the stretch-activated cation channel in vertebrate cells. Nat Cell Biol 2005;7(2):179-185.
255. Matsumura CY, Taniguti AP, Pertille A, Santo Neto H, Marques MJ. Stretch-activated calcium channel protein TRPC1 is correlated with the different degrees of the dystrophic phenotype in mdx mice. Am J Physiol Cell Physiol 2011;301(6):C1344-C1350.
256. Vandebrouck C, Martin D, Colson-Van Schoor M, Debaix H, Gailly P. Involvement of TRPC in the abnormal calcium influx observed in dystrophic (mdx) mouse skeletal muscle fibers. J Cell Biol 2002;158(6):1089-1096.
257. Millay DP, Goonasekera SA, Sargent MA, Maillet M, Aronow BJ, Molkentin JD. Calcium influx is sufficient to induce muscular dystrophy through a TRPC-dependent mechanism. Proc Natl Acad Sci USA 2009;106(45):19023-19028.
258. Jørgensen LH, Blain A, Greally E, Laval SH, Blamire AM, Davison BJ, Brinkmeier H, MacGowan GA, Schrøder HD, Bushby K, Straub V, Lochmüller H. Long-term blocking of calcium channels in mdx mice results in differential effects on heart and skeletal muscle. Am J Pathol 2011;178(1):273-283.
259. 2+-permeable growth factor-regulated channel. J Cell Biol 2003;161(5):957-967.
260. Kaprielian RR, Stevenson S, Rothery SM, Cullen MJ, Severs NJ. Distinct patterns of dystrophin organization in myocyte sarcolemma and transverse tubules of normal and diseased human myocardium. Circulation 2000;101(22):2586-2594.
261. Lohan J, Culligan K, Ohlendieck K. Deficiency in cardiac dystrophin affects the abundance of the α-/β-dystroglycan complex. J Biomed Biotechnol 2005;2005(1):28-36.
262. Meng H, Leddy JJ, Frank J, Holland P, Tuana BS. The association of cardiac dystrophin with myofibrils/Z-disc regions in cardiac muscle suggests a novel role in the contractile apparatus. J Biol Chem 1996;271(21):12364-12371.
263. Peri V, Ajdukovic B, Holland P, Tuana BS. Dystrophin predominantly localizes to the transverse tubule/Z-line regions of single ventricular myocytes and exhibits distinct associations with the membrane. Mol Cell Biochem 1994;130(1):57-65.
264. Pons F, Robert A, Fabbrizio E, Hugon G, Califano JC, Fehrentz JA, Martinez J, Mornet D. Utrophin localization in normal and dystrophin-deficient heart. Circulation 1994;90(1):369-374.
265. Vohra MS, Komiyama M, Hayakawa K, Obinata T, Shimada Y. Subcellular localization of dystrophin and vinculin in cardiac muscle fibers and fibers of the conduction system of the chicken ventricle. Cell Tissue Res 1998;294(1):137-143.
266. Rohman MS, Emoto N, Takeshima Y, Yokoyama M, Matsuo M. Decreased mAKAP, ryanodine receptor, and SERCA2a gene expression in mdx hearts. Biochem Biophys Res Commun 2003;310(1):228-235.
267. 2+ is elevated at all ages. J Neurol Sci 1991;103(2):226-231.
268. Alloatti G, Gallo MP, Penna C, Levi RC. Properties of cardiac cells from dystrophic mouse. J Mol Cell Cardiol 1995;27(8):1775-1779.
269. 2+ influx into dystrophic mdx cardiomyocytes. Cell Calcium 2009;46(2):114-121.
270. Spurney C, Guerron A, Yu Q, Sali A, van der Meulen J, Hoffman E, Nagaraju K. Membrane sealant poloxamer P188 protects against isoproterenol induced cardiomyopathy in dystrophin deficient mice. BMC Cardiovasc Disord 2011;11(1):20.
271. Yasuda S, Townsend D, Michele DE, Favre EG, Day SM, Metzger JM. Dystrophic heart failure blocked by membrane sealant poloxamer. Nature 2005;436(7053):1025-1029.
272. Townsend D, Turner I, Yasuda S, Martindale J, Davis J, Shillingford M, Kornegay JN, Metzger JM. Chronic administration of membrane sealant prevents severe cardiac injury and ventricular dilatation in dystrophic dogs. J Clin Invest 2010;120(4):1140-1150.
273. Koenig X, Dysek S, Kimbacher S, Mike AK, Cervenka R, Lukacs P, Nagl K, Dang XB, Todt H, Bittner RE, Hilber K. Voltage-gated ion channel dysfunction precedes cardiomyopathy development in the dystrophic heart. PLoS One 2011;6(5):e20300.
274. Guharay F, Sachs F. Stretch-activated single ion channel currents in tissue-cultured embryonic chick skeletal muscle. J Physiol 1984;352:685-701.
275. Fauconnier J, Thireau J, Reiken S, Cassan C, Richard S, Matecki S, Marks AR, Lacampagne A. Leaky RyR2 trigger ventricular arrhythmias in Duchenne muscular dystrophy. Proc Natl Acad Sci USA 2010;107(4):1559-1564.
276. Chaubourt E, Voisin V, Fossier P, Baux G, Israël M, De La Porte S. Muscular nitric oxide synthase (muNOS) and utrophin. J Physiol Paris 2002;96(1-2):43-52.
277. Gath I, Closs EI, Godtel-Armbrust U, Schmitt S, Nakane M, Wessler I, Forstermann U. Inducible NO synthase II and neuronal NO synthase I are constitutively expressed in different structures of guinea pig skeletal muscle: Implications for contractile function. FASEB J 1996;10(14):1614-1620.
278. Kobzik L, Stringer B, Balligand JL, Reid MB, Stamler JS. Endothelial type nitric oxide synthase in skeletal muscle fibers: Mitochondrial relationships. Biochem Biophys Res Commun 1995;211(2):375-381.
279. Nakane M, Schmidt HH, Pollock JS, Forstermann U, Murad F. Cloned human brain nitric oxide synthase is highly expressed in skeletal muscle. FEBS Lett 1993;316(2):175-180.
280. Punkt K, Naupert A, Wellner M, Asmussen G, Schmidt C, Buchwalow IB. Nitric oxide synthase II in rat skeletal muscles. Histochem Cell Biol 2002;118(5):371-379.
281. Vallance P. Nitric oxide: Therapeutic opportunities. Fundam Clin Pharmacol 2003;17(1):1-10.
282. Reid MB. Role of nitric oxide in skeletal muscle: Synthesis, distribution and functional importance. Acta Physiol Scand 1998;162(3):401-409.
283. Stamler JS, Meissner G. Physiology of nitric oxide in skeletal muscle. Physiol Rev 2001;81(1):209-237.
284. Grozdanovic Z. NO message from muscle. Microsc Res Tech 2001;55(3):148-153.
285. De Palma C, Clementi E. Nitric oxide in myogenesis and therapeutic muscle repair. Mol Neurobiol 2012;46(3):1-11.
286. Percival JM, Anderson KN, Huang P, Adams ME, Froehner SC. Golgi and sarcolemmal neuronal NOS differentially regulate contraction-induced fatigue and vasoconstriction in exercising mouse skeletal muscle. J Clin Invest 2010;120(3):816-826.
287. Chang WJ, Iannaccone ST, Lau KS, Masters BS, McCabe TJ, McMillan K, Padre RC, Spencer MJ, Tidball JG, Stull JT. Neuronal nitric oxide synthase and dystrophin-deficient muscular dystrophy. Proc Natl Acad Sci USA 1996;93(17):9142-9147.
288. Adams ME, Butler MH, Dwyer TM, Peters MF, Murnane AA, Froehner SC. Two forms of mouse syntrophin, a 58 kd dystrophin-associated protein, differ in primary structure and tissue distribution. Neuron 1993;11(3):531-540.
289. Lai Y, Thomas GD, Yue Y, Yang HT, Li D, Long C, Judge L, Bostick B, Chamberlain JS, Terjung RL, Duan D. Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J Clin Invest 2009;119(3):624-635.
290. Kameya S, Miyagoe Y, Nonaka I, Ikemoto T, Endo M, Hanaoka K, Nabeshima Y, Takeda S. α1-syntrophin gene disruption results in the absence of neuronal-type nitric-oxide synthase at the sarcolemma but does not induce muscle degeneration. J Biol Chem 1999;274(4):2193-2200.
291. Crosbie RH, Straub V, Yun HY, Lee JC, Rafael JA, Chamberlain JS, Dawson VL, Dawson TM, Campbell KP. mdx muscle pathology is independent of nNOS perturbation. Hum Mol Genet 1998;7(5):823-829.
292. Xu KY, Huso DL, Dawson TM, Bredt DS, Becker LC. Nitric oxide synthase in cardiac sarcoplasmic reticulum. Proc Natl Acad Sci USA 1999;96(2):657-662.
293. Barouch LA, Harrison RW, Skaf MW, Rosas GO, Cappola TP, Kobeissi ZA, Hobai IA, Lemmon CA, Burnett AL, O'Rourke B, Rodriguez ER, Huang PL, Lima JA, Berkowitz DE, Hare JM. Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nature 2002;416(6878):337-339.
294. Burkard N, Rokita AG, Kaufmann SG, Hallhuber M, Wu R, Hu K, Hofmann U, Bonz A, Frantz S, Cartwright EJ, Neyses L, Maier LS, Maier SK, Renne T, Schuh K, Ritter O. Conditional neuronal nitric oxide synthase overexpression impairs myocardial contractility. Circ Res 2007;100(3):e32-e44.
295. Xu KY, Kuppusamy SP, Wang JQ, Li H, Cui H, Dawson TM, Huang PL, Burnett AL, Kuppusamy P, Becker LC. Nitric oxide protects cardiac sarcolemmal membrane enzyme function and ion active transport against ischemia-induced inactivation. J Biol Chem 2003;278(43):41798-41803.
296. Williams JC, Armesilla AL, Mohamed TM, Hagarty CL, McIntyre FH, Schomburg S, Zaki AO, Oceandy D, Cartwright EJ, Buch MH, Emerson M, Neyses L. The sarcolemmal calcium pump, α-1 syntrophin, and neuronal nitric-oxide synthase are parts of a macromolecular protein complex. J Biol Chem 2006;281(33):23341-23348.
297. Luz MA, Marques MJ, Santo Neto H. Impaired regeneration of dystrophin-deficient muscle fibers is caused by exhaustion of myogenic cells. Braz J Med Biol Res 2002;35(6):691-695.
298. Marques MJ, Luz MAM, Minatel E, Neto HS. Muscle regeneration in dystrophic mdx mice is enhanced by isosorbide dinitrate. Neurosci Lett 2005;382(3):342-345.
299. 2+ regulation: Potential mechanisms of its myotoxicity. Anesthesiology 2002;97(3):710-716.
300. 2+ regulation in murine skeletal muscle fibers. Anesthesiology 2005;102(4):793-798.
301. Zink W, Seif C, Bohl JR, Hacke N, Braun PM, Sinner B, Martin E, Fink RH, Graf BM. The acute myotoxic effects of bupivacaine and ropivacaine after continuous peripheral nerve blockades. Anesth Analg 2003;97(4):1173-1179.
302. Brunelli S, Sciorati C, D'Antona G, Innocenzi A, Covarello D, Galvez BG, Perrotta C, Monopoli A, Sanvito F, Bottinelli R, Ongini E, Cossu G, Clementi E. Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy. Proc Natl Acad Sci USA 2007;104(1):264-269.
303. Thomas GD, Sander M, Lau KS, Huang PL, Stull JT, Victor RG. Impaired metabolic modulation of α-adrenergic vasoconstriction in dystrophin-deficient skeletal muscle. Proc Natl Acad Sci USA 1998;95(25):15090-15095.
304. Sander M, Chavoshan B, Harris SA, Iannaccone ST, Stull JT, Thomas GD, Victor RG. Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy. Proc Natl Acad Sci USA 2000;97(25):13818-13823.
305. Crosbie RH. NO vascular control in Duchenne muscular dystrophy. Nat Med 2001;7(1):27-29.
306. Chao DS, Silvagno F, Bredt DS. Muscular dystrophy in mdx mice despite lack of neuronal nitric oxide synthase. J Neurochem 1998;71(2):784-789.
307. Lau KS, Grange RW, Chang W-J, Kamm KE, Sarelius I, Stull JT. Skeletal muscle contractions stimulate cGMP formation and attenuate vascular smooth muscle myosin phosphorylation via nitric oxide. FEBS Lett 1998;431(1):71-74.
308. Thompson M, Becker L, Bryant D, Williams G, Levin D, Margraf L, Giroir BP. Expression of the inducible nitric oxide synthase gene in diaphragm and skeletal muscle. J Appl Physiol 1996;81(6):2415-2420.
309. Louboutin JP, Rouger K, Tinsley JM, Halldorson J, Wilson JM. iNOS expression in dystrophinopathies can be reduced by somatic gene transfer of dystrophin or utrophin. Mol Med 2001;7(5):355-364.
310. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004;25(12):677-686.
311. Li D, Shin JH, Duan D. iNOS ablation does not improve specific force of the extensor digitorum longus muscle in dystrophin-deficient mdx4cv mice. PLoS One 2011;6(6):e21618.
312. Villalta SA, Nguyen HX, Deng B, Gotoh T, Tidball JG. Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy. Hum Mol Genet 2009;18(3):482-496.
313. Wehling-Henricks M, Jordan MC, Gotoh T, Grody WW, Roos KP, Tidball JG. Arginine metabolism by macrophages promotes cardiac and muscle fibrosis in mdx muscular dystrophy. PLoS One 2010;5(5):e10763.
314. Bauer PM, Buga GM, Fukuto JM, Pegg AE, Ignarro LJ. Nitric oxide inhibits ornithine decarboxylase via S-nitrosylation of cysteine 360 in the active site of the enzyme. J Biol Chem 2001;276(37):34458-34464.
315. Witte MB, Barbul A. Arginine physiology and its implication for wound healing. Wound Repair Regen 2003;11(6):419-423.
316. Bellinger AM, Reiken S, Carlson C, Mongillo M, Liu X, Rothman L, Matecki S, Lacampagne A, Marks AR. Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle. Nat Med 2009;15(3):325-330.
317. Crisp A, Yin H, Goyenvalle A, Betts C, Moulton HM, Seow Y, Babbs A, Merritt T, Saleh AF, Gait MJ, Stuckey DJ, Clarke K, Davies KE, Wood MJA. Diaphragm rescue alone prevents heart dysfunction in dystrophic mice. Hum Mol Genet 2011;20(3):413-421.
318. Gilroy J, Cahalan JL, Berman R, Newman M. Cardiac and pulmonary complications in Duchenne's progressive muscular dystrophy. Circulation 1963;27(4 Pt 1):484-493.
319. Yotsukura M, Miyagawa M, Tsua T, Ishihara T, Ishikawa K. Pulmonary hypertension in progressive muscular dystrophy of the Duchenne type. Jpn Circ J 1988;52(4):321-326.
320. Cohn RD, van Erp C, Habashi JP, Soleimani AA, Klein EC, Lisi MT, Gamradt M, ap Rhys CM, Holm TM, Loeys BL, Ramirez F, Judge DP, Ward CW, Dietz HC. Angiotensin II type 1 receptor blockade attenuates TGF-β-induced failure of muscle regeneration in multiple myopathic states. Nat Med 2007;13(2):204-210.
321. Spurney CF, Sali A, Guerron AD, Iantorno M, Yu Q, Gordish-Dressman H, Rayavarapu S, van der Meulen J, Hoffman EP, Nagaraju K. Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice. J Cardiovasc Pharmacol Ther 2011;16(1):87-95.
322. Meune C, Mahe I, Mourad JJ, Simoneau G, Knellwolf AL, Bergmann JF, Caulin C. Interaction between angiotensin-converting enzyme inhibitors and aspirin: A review. Eur J Clin Pharmacol 2000;56(9-10):609-620.
323. Gazzerro E, Assereto S, Bonetto A, Sotgia F, Scarfi S, Pistorio A, Bonuccelli G, Cilli M, Bruno C, Zara F, Lisanti MP, Minetti C. Therapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophies. Am J Pathol 2010;176(4):1863-1877.
324. Martin MM, Buckenberger JA, Jiang J, Malana GE, Knoell DL, Feldman DS, Elton TS. TGF-β1 stimulates human AT1 receptor expression in lung fibroblasts by cross talk between the Smad, p38 MAPK, JNK, and PI3K signaling pathways. Am J Physiol Lung Cell Mol Physiol 2007;293(3):L790-799.
325. Russell ST, Wyke SM, Tisdale MJ. Mechanism of induction of muscle protein degradation by angiotensin II. Cell Signal 2006;18(7):1087-1096.
326. Bauer R, Straub V, Blain A, Bushby K, MacGowan GA. Contrasting effects of steroids and angiotensin-converting-enzyme inhibitors in a mouse model of dystrophin-deficient cardiomyopathy. Eur J Heart Fail 2009;11(5):463-471.
327. Cozzoli A, Nico B, Sblendorio VT, Capogrosso RF, Dinardo MM, Longo V, Gagliardi S, Montagnani M, De Luca A. Enalapril treatment discloses an early role of angiotensin II in inflammation- and oxidative stress-related muscle damage in dystrophic mdx mice. Pharmacol Res 2011;64(5):482-492.
328. Duboc D, Meune C, Lerebours G, Devaux JY, Vaksmann G, Becane HM. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol 2005;45(6):855-857.
329. Duboc D, Meune C, Pierre B, Wahbi K, Eymard B, Toutain A, Berard C, Vaksmann G, Weber S, Becane HM. Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years' follow-up. Am Heart J 2007;154(3):596-602.
330. Rafael-Fortney JA, Chimanji NS, Schill KE, Martin CD, Murray JD, Ganguly R, Stangland JE, Tran T, Xu Y, Canan BD, Mays TA, Delfin DA, Janssen PM, Raman SV. Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in Duchenne muscular dystrophy mice. Circulation 2011;124(5):582-588.
331. Hor KN, Mazur W, Taylor MD, Al-Khalidi HR, Cripe LH, Jefferies JL, Raman SV, Chung ES, Kinnett KJ, Williams K, Gottliebson WM, Benson DW. Effects of steroids and angiotensin converting enzyme inhibition on circumferential strain in boys with Duchenne muscular dystrophy: A cross-sectional and longitudinal study utilizing cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2011;13:60.
332. Barton-Davis ER, Cordier L, Shoturma DI, Leland SE, Sweeney HL. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest 1999;104(4):375-381.
333. De Luca A, Pierno S, Liantonio A, Cetrone M, Camerino C, Fraysse B, Mirabella M, Servidei S, Rüegg UT, Conte Camerino D. Enhanced Dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1. J Pharmacol Exp Ther 2003;304(1):453-463.
334. Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P, Paushkin S, Patel M, Trotta CR, Hwang S, Wilde RG, Karp G, Takasugi J, Chen G, Jones S, Ren H, Moon YC, Corson D, Turpoff AA, Campbell JA, Conn MM, Khan A, Almstead NG, Hedrick J, Mollin A, Risher N, Weetall M, Yeh S, Branstrom AA, Colacino JM, Babiak J, Ju WD, Hirawat S, Northcutt VJ, Miller LL, Spatrick P, He F, Kawana M, Feng H, Jacobson A, Peltz SW, Sweeney HL. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007;447(7140):87-91.
335. Hoffman EP, Bronson A, Levin AA, Takeda S, Yokota T, Baudy AR, Connor EM. Restoring dystrophin expression in Duchenne muscular dystrophy muscle progress in exon skipping and stop codon read through. Am J Pathol 2011;179(1):12-22.
336. Koenig M, Hoffman EP, Bertelson CJ, Monaco AP, Feener C, Kunkel LM. Complete cloning of the duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 1987;50(3):509-517.
337. Roberts RG, Coffey AJ, Bobrow M, Bentley DR. Exon structure of the human dystrophin gene. Genomics 1993;16(2):536-538.
338. Mendell JR, Campbell K, Rodino-Klapac L, Sahenk Z, Shilling C, Lewis S, Bowles D, Gray S, Li C, Galloway G, Malik V, Coley B, Clark KR, Li J, Xiao X, Samulski J, McPhee SW, Samulski RJ, Walker CM. Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med 2010;363(15):1429-1437.
339. Pichavant C, Aartsma-Rus A, Clemens PR, Davies KE, Dickson G, Takeda S, Wilton SD, Wolff JA, Wooddell CI, Xiao X, Tremblay JP. Current status of pharmaceutical and genetic therapeutic approaches to treat DMD. Mol Ther 2011;19(5):830-840.
340. Jearawiriyapaisarn N, Moulton HM, Sazani P, Kole R, Willis MS. Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers. Cardiovasc Res 2010;85(3):444-453.
341. Lu QL, Rabinowitz A, Chen YC, Yokota T, Yin H, Alter J, Jadoon A, Bou-Gharios G, Partridge T. Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci USA 2005;102(1):198-203.
342. Wu B, Xiao B, Cloer C, Shaban M, Sali A, Lu P, Li J, Nagaraju K, Xiao X, Lu QL. One-year treatment of morpholino antisense oligomer improves skeletal and cardiac muscle functions in dystrophic mdx mice. Mol Ther 2011;19(3):576-583.
343. Sears CE, Bryant SM, Ashley EA, Lygate CA, Rakovic S, Wallis HL, Neubauer S, Terrar DA, Casadei B. Cardiac neuronal nitric oxide synthase isoform regulates myocardial contraction and calcium handling. Circ Res 2003;92(5):e52-e59.
344. Mizunoya W, Upadhaya R, Burczynski FJ, Wang G, Anderson JE. Nitric oxide donors improve prednisone effects on muscular dystrophy in the mdx mouse diaphragm. Am J Physiol Cell Physiol 2011;300(5):C1065-C1077.
345. Adamo CM, Dai DF, Percival JM, Minami E, Willis MS, Patrucco E, Froehner SC, Beavo JA. Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy. Proc Natl Acad Sci USA 2010;107(44):19079-19083.
346. Khairallah M, Khairallah RJ, Young ME, Allen BG, Gillis MA, Danialou G, Deschepper CF, Petrof BJ, Des Rosiers C. Sildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiency. Proc Natl Acad Sci USA 2008;105(19):7028-7033.